Erasca, Inc.【ERAS】

時価総額

$38.3億

PER

臨床段階の精密腫瘍医薬品開発の新興企業。RAS/MAPK経路を標的とするナポラフェニブ第III相試験、パンクRAS阻害剤を展開。2024年5月の増資で1.74億ドル、2024年4月の私募で4360万ドルを調達。米国・欧州中心に展開。

	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-123	-243	-125	-162
Depreciation and amortization	829,000	3	4	4
Stock-based compensation expense	8	20	26	27
In-process research and development	-	-	-	23
Accretion on marketable securities, net	-0	1	7	10
Impairment charge on operating lease assets and property and equipment	-	-	-	5
Impairment charge on investment in equity securities	-	-	-	2
Prepaid expenses and other current and long-term assets	7	4	-1	2
Accounts payable	1	1	-1	-2
Accrued expenses and other current and long-term liabilities	-	5	-2	6
Operating lease assets and liabilities, net	-1	-14	-3	1
Net cash used in operating activities	-80	-103	-101	-109
Purchases of marketable securities	-	132	314	403
Maturities of marketable securities	-	80	245	269
In-process research and development	8	2	20	23
Payment made for investment in equity securities	-	2	-	0
Purchases of property and equipment	11	15	2	0
Net cash used in investing activities	-65	-71	-91	-157
Proceeds from Issuance of Private Placement	-	-	-	44
Underwritten Offering	-	-	-	174
ATM Offering	-	-	-	21
Proceeds from issuance of common stock	-	95	-	-
Proceeds from Stock Options Exercised	1	2	1	1
Proceeds from issuance of common stock under the Employee Stock Purchase Plan	1	1	1	1
Net cash provided by financing activities	439	98	1	241
Net decrease in cash, cash equivalents and restricted cash	295	-76	-191	-25
Issuance of common stock to Erasca Foundation	-17	-	-	-
Issuance of common stock in connection with asset acquisition	2	-	-	-
Issuance of common stock in connection with license agreement	5	80	-	-
Amounts accrued for in-process research and development expenses	-	20	-	-
Amounts Accrued For Purchase Of Property And Equipment	4	1	0	-
Amounts accrued for offering costs	-	0	-	-
Conversion of Stock, Amount Issued	341	-	-	-
Vesting of early exercised options	1	1	1	0
Operating lease assets obtained in exchange for lease obligation	17	23	-	-
Reduction in operating lease assets due to lease amendment	1	3	-	-
Tenant improvement allowance included in operating lease liabilities	17	-	-	-